Conditionnement : 1mLx10mM(inDMSO)
Téléphone : +1 850 650 7790
Synonyms: NEM, Ethylmaleimide, 1-Ethyl-1H-pyrrole-2,5-dione
| Description | N-Ethylmaleimide (NEM) is a reagent for alkylation of free sulfhydryl groups, a cysteine protease inhibitor used in experimental biochemistry. N-Ethylmaleimide is also a deubiquitinating enzyme inhibitor that specifically inhibits phosphate transport in mitochondria. |
| Targets & IC50 | prolyl endopeptidase:6.3 μM, COS-7 cells:43.7 μM (EC50), KB-3-1 cells:0.03 mM, SF-268 cells:6.5 μg/mL (GL50), KB-V1 cells:0.016 mM, MCF-7 cells:9.9 μg/mL (GL50), NCI-H4 cells:6.7 μg/mL (GL50) |
| In vitro | METHODS: Growth-arrested VSMC cells were treated with N-Ethylmaleimide (20 µM) and PDGF-BB (20 ng/mL) for 5 min - 2 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: N-Ethylmaleimide inhibited PDGF BB-stimulated Akt phosphorylation. [1] METHODS: Jurkat T cells were treated with N-Ethylmaleimide (3-100 µM) for 1-20 min, and target protein expression levels were detected by immunoblots. RESULTS: Treatment of intact cells with 50-100 µM N-Ethylmaleimide for 5-10 min resulted in a significant increase in tyrosine residue phosphorylation. [2] |
| In vivo | METHODS: To examine the potential enhancement of sleep properties induced by alprazolam (Alp), N-Ethylmaleimide (1 mg/kg, 1% CMC-Na) and Alp (1.84 mg/kg, 1% CMC-Na) were administered by gavage to C57BL/6J mice. RESULTS: Combined administration of Alp and NEM significantly reduced sleep latency and prolonged sleep duration compared with Alp alone. This effect was characterized by a significant increase in REM duration. [3] |
| Synonyms | NEM, Ethylmaleimide, 1-Ethyl-1H-pyrrole-2,5-dione |
| Molecular Weight | 125.13 |
| Formula | C6H7NO2 |
| Cas No. | 128-53-0 |
| Smiles | C(C)N1C(=O)C=CC1=O |
| Relative Density. | 1.207 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 237.5 mg/mL (1898.03 mM), Sonication is recommended.  H2O: 50 mg/mL (399.58 mM), Sonication and heating are recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 5% DMSO+95% Saline: 1.2 mg/mL (9.59 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
